Venus Remedies Joins AMR Vivli to Combat Antimicrobial Resistance
Venus Remedies is proud to announce its official membership in AMR Vivli, a global platform dedicated to sharing critical data on antimicrobial resistance (AMR). Supported by the Wellcome Trust, AMR Vivli provides a crucial platform for researchers, healthcare organizations, and industry leaders to collaborate in combating AMR, which has become one of the most urgent public health threats in recent years. This partnership highlights Venus' continued dedication to tackling the growing global threat of AMR.
AMR occurs when bacteria and other such pathogens evolve to resist the drugs designed to treat infections, making antibiotics less effective. The WHO has identified AMR as a critical threat that could lead to a future where routine medical procedures and surgeries become high-risk due to the lack of effective antibiotics.
Venus Remedies has long been committed to combating AMR through research, innovation, and global collaborations, such as the AMR Industry Alliance, reflecting its dedication to this cause. The AMR Industry Alliance unites pharmaceutical companies, industry groups, and researchers to promote the responsible use of antibiotics, encourage new antimicrobial drug development, and advocate for public policies that can reduce the spread of resistance.
AMR Vivli seeks to enable innovative re-use of surveillance data shared by its nine-member companies - GSK, Johnson & Johnson, Merck, Pfizer, Shionogi, Viatris, Paratek, Venatorx, and Venus Remedies. Vivli was funded by Wellcome in June 2022 to launch the AMR Register (amr.vivli.org). This Register provides access to high-quality antimicrobial susceptibility surveillance data (MIC by organism) generated by the pharmaceutical industry.
By sharing their data via the AMR Register, pharmaceutical companies thereby uphold their agreements with regards to data transparency. Nine member companies have contributed data on more than 1,000,000 isolates from 89 countries! And Venus is one of these companies.
Basically, AMR Vivli enables members to share and access critical data on AMR trends and resistance patterns, promoting a more coordinated response to this pressing challenge. Venus will contribute valuable data and insights to this platform, which will be used by researchers, policymakers, and other healthcare professionals to develop more effective strategies to combat AMR.
This collaboration enhances Venus’s ability to make a meaningful impact on the global AMR crisis, allowing the company to be part of a broader, unified effort to reduce the spread of resistant infections. It also opens the door to working closely with other experts and organizations that are equally committed to finding solutions to this global health emergency.
To learn more about our membership with AMR Vivli and its ongoing efforts to fight AMR, visit:
Source - https://ns2.amr.solutions/2024/10/20/vivli-access-to-industrys-susceptibility-surveillance-data/
